Acer Therapeutics And Relief Therapeutics Announce Submission Of A New Drug Application To The FDA For ACER-001 For Treatment Of Urea Cycle Disorders
Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer"), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant